» Articles » PMID: 37937607

KLF4 Suppresses the Proliferation of Perihilar Cholangiocarcinoma by Negatively Regulating GDF15 and Phosphorylating AKT

Overview
Journal Oncol Rep
Specialty Oncology
Date 2023 Nov 8
PMID 37937607
Authors
Affiliations
Soon will be listed here.
Abstract

Krüppel‑like factor 4 (KLF4) is a transcription factor which functions as a tumor suppressor or an oncogene in numerous types of solid tumors. However, its expression levels and function in perihilar cholangiocarcinoma (pCCA) have yet to be elucidated. In the present study, in order to investigate its roles in pCCA, reverse transcription‑quantitative PCR (RT‑qPCR), western blot analysis and immunohistochemistry were used to detect KLF4 expression in pCCA. The Chi‑squared test was used to analyze the associations between KLF4 and the clinicopathological features of patients with pCCA. Univariate and multivariate analyses were subsequently used to analyze the prognostic significance of KLF4. The tumor suppression of KLF4 was investigated for the purposes of illustrating its biological function both and . Furthermore, the association between KLF4 and growth/differentiation factor 15 (GDF15) was determined using pCCA tissue microarray (TMA) analysis and RT‑qPCR. The underlying molecular mechanisms between KLF4 and GDF15 were subsequently investigated . In pCCA tissues, KLF4 was found to be downregulated, and this was negatively associated with the histological grade and tumor size. The knockdown of KLF4 was also found to be a prognostic indicator of the poorer survival of patients with pCCA. Based on and analyses, KLF4 was found to suppress tumor progression and induce cell apoptosis. Furthermore, it was found that KLF4 executed its tumor suppressive effects via the regulation of the GDF15/AKT signaling pathway. Taken together, the findings of the present study demonstrate that KLF4 may be considered as an independent biomarker of a favorable prognosis of patients with pCCA, and the KLF4/GDF15/AKT signaling pathway may potentially be a novel molecular therapeutic target for patients with pCCA.

Citing Articles

KLF4: a multifunctional nexus connecting tumor progression and immune regulation.

Ju Y, Xiao W, Mathis B, Shi Y Front Immunol. 2025; 16:1514780.

PMID: 39995670 PMC: 11848521. DOI: 10.3389/fimmu.2025.1514780.


Comprehensive landscape and oncogenic role of extrachromosomal circular DNA in malignant biliary strictures.

Cheng Z, Luo X, Liu W, Lu X, Chang H, Wang Y Cell Biosci. 2025; 15(1):16.

PMID: 39920810 PMC: 11804034. DOI: 10.1186/s13578-025-01361-6.


The COL7A1/PI3K/AKT axis regulates the progression of cholangiocarcinoma.

Ma Y, Zhang Y, Chen F, Liu S, Wang D, Lu Z Heliyon. 2024; 10(18):e37361.

PMID: 39309925 PMC: 11415666. DOI: 10.1016/j.heliyon.2024.e37361.

References
1.
Xu Q, Xu H, Li J, Wang S, Fu Z, Jia J . Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling. Oncotarget. 2017; 8(10):16972-16987. PMC: 5370015. DOI: 10.18632/oncotarget.15216. View

2.
Li C, Wang J, Kong J, Tang J, Wu Y, Xu E . GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 2015; 7(1):860-72. PMC: 4808038. DOI: 10.18632/oncotarget.6205. View

3.
Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

4.
Hu W, Jia Y, Xiao X, Lv K, Chen Y, Wang L . KLF4 downregulates hTERT expression and telomerase activity to inhibit lung carcinoma growth. Oncotarget. 2016; 7(33):52870-52887. PMC: 5288155. DOI: 10.18632/oncotarget.9141. View

5.
Modi A, Purohit P, Roy D, Vishnoi J, Pareek P, Elhence P . FOXM1 mediates GDF-15 dependent stemness and intrinsic drug resistance in breast cancer. Mol Biol Rep. 2022; 49(4):2877-2888. DOI: 10.1007/s11033-021-07102-5. View